Ultragenyx

Ultragenyx (operating at ultragenyx.com) is a biopharmaceutical company engineered for developing therapies for people living with rare and ultra-rare genetic diseases. Founded in 2010 by Emil Kakkis and headquartered in Novato, California, Ultragenyx focuses on developing first-ever approved treatments for rare and ultrarare diseases and moving the rare disease community forward. Under the hood, the company identifies, acquires, develops, and commercializes novel products for treatment of rare and ultrarare diseases. This allows patients and families affected by these diseases to access innovative treatments and improve their quality of life. Backed by significant funding, including a valuation of $271 million in 2020.